The Promise and the Pitfall of Clascaderone
Headlines have been singing a siren song about a new hair loss medication, Clascaderone, with some claiming hundreds of percent improvements in hair count. But before we get carried away by the numbers, let's step back and ask what those numbers actually mean for a person looking in the mirror. Are we measuring the drug the right way? To answer that, we need to look beyond the marketing language and examine its mechanism, the trial design, and the real-world cosmetic change that matters most.
How Clascaderone Actually Works
Androgenetic alopecia, the most common form of hair loss in both men and women, is largely driven by dihydrotestosterone (DHT). DHT attaches to androgen receptors in hair follicles and slowly miniaturizes them. Current treatments like finasteride work by lowering DHT levels, but they can come with systemic side effects. Enter Clascaderone: a topically applied androgen receptor inhibitor. Instead of reducing DHT, it competes with DHT for the same binding spot on the receptor. The chemical structures of Clascaderone and DHT are strikingly similar, and Clascaderone actually has a higher affinity for those receptors. It acts as a competitive antagonist, physically blocking DHT from docking and exerting its damaging downstream effects. This local action is key: Clascaderone is rapidly metabolized into an inactive form (cortezolone) right in the skin, which minimizes the risk of systemic anti-androgenic side effects. That's the theoretical advantage—a way to fight DHT at the scalp without the hormone-level disruptions of oral medications.
The Early Trials: Hints, Flaws, and Unpublished Data
What we know from the early studies comes mainly from a single abstract published in 2019, summarizing in vitro, phase 1, and phase 2 results. Why only an abstract? That's a red flag worth noting. The phase 1 study was tiny—just 18 patients in one center, lasting only 28 days. They applied a 5% Clascaderone solution, and 72% of participants reported at least one treatment-emergent adverse event, mostly mild local skin reactions like redness, scaling, and dryness. The likely culprit is propylene glycol, the same vehicle found in many topical minoxidil solutions. The phase 2 studies, which included 70 and 95 patients respectively, compared Clascaderone against other anti-androgens and minoxidil. While Clascaderone showed numerically greater hair count changes than the vehicle, the results did not reach statistical significance. One comparison yielded a p-value of 0.0971, another a p-value of 0.2213—well above the conventional 0.05 threshold. Also worth remembering: the research was conducted by Cosmo Pharmaceuticals, the company developing the drug, adding a layer of potential bias.
The Phase 3 Hype: Big Percentages, Small Actual Gains?
In 2025, Cosmo announced promising phase 3 results from two trials called SCALP-1 and SCALP-2. These were multi-center, randomized, double-blind, vehicle-controlled studies involving 1,465 men across the US and Europe. Yet as of early 2026, we still lack a full peer-reviewed publication—only press releases. According to those releases, the drug produced a 539% relative improvement in target area hair count in one study and a 168% relative improvement in the other. Those are dizzying numbers. But relative percentages can hide tiny absolute differences. Imagine the Clascaderone group gained 7 hairs per square centimeter while the vehicle group gained 1.1. The arithmetic gives you a 539% relative improvement, but the absolute difference is only about 6 hairs per square centimeter—unlikely to create the kind of visible change a person would notice. When you look at the photographic results Cosmo released, the lighting inconsistencies are obvious: stronger flash in the before images creates artificial contrast, making the after images appear darker. Even if there is some genuine regrowth, the transformation seems modest compared to what we see with established treatments like finasteride and minoxidil.
Comparing to the Gold Standards
Consider a patient who underwent a hair transplant and was also placed on minoxidil and finasteride. A year later, without any surgery on the crown, that area showed dramatic improvement—thicker, healthier hair. The donor area looked better too. That's the real power of finasteride and minoxidil. By contrast, Clascaderone's results, at least in the images published so far, do not seem to match that level of benefit. And even if the drug is approved, cost will be a major hurdle. A 60-gram tube of Winlevi (the acne formulation) costs $600 to $800, and you'd need 1.5 to 3 grams for the DHT-sensitive zones, meaning one tube lasts about a month. That's potentially $800 per month. Compare that to proven topical finasteride medications available for around $40 per month. New does not always mean better, especially when the price tag is twenty times higher.
A Different Lens: Maintenance Over Regrowth
Perhaps we are evaluating Clascaderone through the wrong lens. Its mechanism is more akin to finasteride and dutasteride—preventing further loss rather than spurring dramatic new growth. Yet the trials and press releases judge it by hair count increases, a growth metric. The real test for Clascaderone might be whether it can help people hold on to their hair without the systemic side effects of oral anti-androgens. Could it serve as a long-term maintenance drug for those who cannot tolerate traditional medications? That question remains unanswered. For now, the headline numbers are dazzling, but the real value of Clascaderone may lie not in how much hair it grows, but in how safely it protects what you already have.